Dr. Reddy's Laboratories logo

Dr. Reddy's Laboratories(NYSE) RDY

Market Cap$10.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)+1,428%
5 Year+2%
1 Year-7%
1 Month+12%
Premium Feature
Moneyball Superscore
65/100
$13.05
+1.12%
+0.14Today
After hours$13.06+$0.02 (+0.11%)
Dr. Reddy's Laboratories last closing stock price
MetricPriceDate
Last closeUSD 13.072026-10-16
Dr. Reddy's Laboratories stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.73%USD 12.482026-10-09
1 month+11.9%USD 11.682026-09-16
3 month+4.47%USD 12.512026-07-17
Year to date-6.25%USD 13.942025-12-31
1 year-7.43%USD 14.122025-10-16
3 year+0.44%USD 13.012023-10-17
5 year+2.39%USD 12.772021-10-15
Since inception+1,427.76%USD 0.862001-04-11

Dr. Reddy's Laboratories Financials at a Glance

Market Cap

$10.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

₹332.83B

Net Income (TTM)

₹33.17B

EPS (TTM)

$0.45

P/E Ratio

29.36

Dividend

$0.08

Beta (Volatility)

0.42 (Low)

Price

$13.05

Volume

2

Open

$13.00

Previous Close

$13.07

Daily Range

$12.94 - $13.07

52-Week Range

$11.36 - $15.67

Estimated Earnings Date

Oct 23, 2026

RDY News

A hand writing the words EMERGING MARKETS.

What Is an Emerging Market Economy?

Anders BylundSep 14, 2025
GettyImages-1132119369

2 Top Global Value Stocks to Buy Now

Zhiyuan SunJul 8, 2021
pharmaceutical worker wearing protective gear holds pills in hand

Why Is No One Talking About Dr. Reddy's Stock?

James HalleyMay 11, 2021
GettyImages-1141354730

Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

Todd CampbellSep 17, 2020
GettyImages-185955499

Is Dr. Reddy's Laboratories a Buy?

Zhiyuan SunMay 10, 2020
093 legal settlement

Will a $48 Billion Global Settlement End U.S. Opioid Crisis Lawsuits?

Maxx ChatskoOct 23, 2019
GettyImages-493071639

Dr. Reddy's Laboratories Ltd (ADR) Is Tanking Today -- Here's Why

Brian FeroldiJul 26, 2016
15824975276_03f64d355f_z

3 Value Stocks Near 52-Week Lows Worth Buying

Sean WilliamsJan 5, 2016
Page 1

RDY: Motley Fool Moneyball Superscore

65

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited is a global pharmaceutical company based in Hyderabad, India. The company specializes in the manufacturing and marketing of a wide range of pharmaceutical products, including generic and proprietary formulations, active pharmaceutical ingredients, and contract research services.

Products and Services
  • Global Generics segment offers prescription and over-the-counter products
  • Pharmaceutical Services and Active Ingredients division produces active pharmaceutical ingredients
  • Proprietary Products segment focuses on unique pharmaceutical formulations
Growth Outlook
  • Recent quarterly revenue reached INR 81.18 billion, showing strong demand
  • Net income for Q1 2026 was INR 4.45 billion, indicating profitability
  • Partnerships in oncology and immuno-oncology are expected to drive future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of INR 309.67 billion reflects solid performance
  • Net profit margin of 9.99% demonstrates effective cost management
  • Current ratio of 1.90 indicates strong liquidity position
Dr. Reddy's Laboratories Limited operates in the healthcare sector, focusing on drug manufacturing, particularly in specialty and generic drugs. The company has established a robust global presence, catering to diverse therapeutic areas such as oncology, cardiovascular health, and diabetes. The recent financial performance highlights a strong revenue trajectory, with a notable increase in quarterly revenue and net income, showcasing the company's ability to capitalize on market opportunities. The strategic partnerships in oncology further enhance the growth potential, positioning Dr. Reddy's as a key player in the pharmaceutical industry. With a solid liquidity position and effective cost management, the company is well-equipped to navigate future challenges and capitalize on emerging opportunities.
AI Generated • Sep 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

27,527

CEO

Erez Israeli, MBA

Website

www.drreddys.com

Headquarters

Hyderabad, TS 500034, IN

RDY Financials

Key Financial Metrics (TTM)

Gross Margin

50.18%

Operating Margin

10.64%

Net Income Margin

10.00%

Return on Equity

8.88%

Return on Capital

10.97%

Return on Assets

5.75%

Earnings Yield

3.41%

Dividend Yield

0.64%

Payout Ratio

20.11%

Stock Overview

Market Cap

$10.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

832.67M

Volume

2

Avg. Volume

2.90M

Financials (TTM)

Gross Profit

₹166.92B

Operating Income

₹35.20B

EBITDA

₹61.13B

Operating Cash Flow

₹40.99B

Capital Expenditure

-₹25.85B

Free Cash Flow

₹15.15B

Cash & ST Invst.

₹81.43B

Total Debt

₹71.95B

Dr. Reddy's Laboratories Performance Analysis

Dr. Reddy's Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31INR 3,060,162,5016.3%
20242024-03-31INR 3,372,211,74410.2%
20252025-03-31INR 3,850,357,35514.2%
20262026-03-31INR 3,801,955,901-1.3%
Dr. Reddy's Laboratories sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-303.0%
Q32025-12-31-0.9%
Q42026-03-31-12.5%
Q12026-06-306.4%
Dr. Reddy's Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31INR 0.6777.3%
20242024-03-31INR 0.8119.7%
20252025-03-31INR 0.80-0.7%
20262026-03-31INR 0.58-27.4%
Dr. Reddy's Laboratories sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-301.4%
Q32025-12-31-15.8%
Q42026-03-31-81.5%
Q12026-06-3099.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

₹81.18B

-5.0%

Gross Profit

₹37.76B

-22.3%

Gross Margin

46.52%

N/A

Market Cap

$10.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$395.36K

N/A

Employees

27,527

N/A

Net Income

₹4.46B

-68.5%

EBITDA

₹8.34B

-66.1%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

₹81.43B

+22.1%

Total Debt

₹71.95B

+47.9%

Accounts Receivable

₹124.42B

+7.8%

Inventory

₹80.47B

+6.4%

Long Term Debt

₹11.88B

+133.2%

Short Term Debt

₹60.07B

+37.9%

Return on Assets

5.75%

N/A

Return on Invested Capital

8.43%

N/A

Free Cash Flow

-₹4.63B

-203.3%

Operating Cash Flow

-₹927.00M

-106.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMRXAmneal Pharmaceuticals, Inc.
$19.18-0.36%
BHCBausch Health Companies Inc.
$6.30-0.16%
ANIPANI Pharmaceuticals, Inc.
$72.29+0.01%
AMPHAmphastar Pharmaceuticals, Inc.
$25.87-2.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$10.64-11.41%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$49.23+12.81%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.90+7.64%

Questions About RDY

What is the current price of Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories is trading at $13.07 per share.

What is the 52-week range for Dr. Reddy's Laboratories?

Over the past 52 weeks, Dr. Reddy's Laboratories has traded between $11.36 and $15.67.

How much debt does Dr. Reddy's Laboratories have?

As of the most recent reporting period, Dr. Reddy's Laboratories reported total debt of ₹760.12M.

How much cash does Dr. Reddy's Laboratories have on hand?

Dr. Reddy's Laboratories reported ₹118.36M in cash and cash equivalents in its most recent financial results.

What is Dr. Reddy's Laboratories’s dividend yield?

Dr. Reddy's Laboratories currently has a dividend yield of 0.64%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services